Moreover, different pro-inflammatory biomarkers such as C-reactive protein, TNF-a, or IL-6, among others, have been evaluated in the setting of stroke and appear to favor post-stroke complications, including stroke recurrences, poor clinical outcomes, and major adverse cardiovascular events, especially in the setting of large artery atherosclerosis, providing a potential therapeutic target for secondary stroke prevention [13,30,31,32]. This evidence concerns the gene IL6 and Stroke.